Showing results (71-80 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|August 1, 1996
Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary reportK Blum, E R Braverman, R C Wood, et al.Pharmacogenetics|August 1, 1996
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphismT H Sullivan-Klose, B I Ghanayem, D A Bell, et al.Pharmacogenetics|August 1, 1996
PCR-based genotyping for duplicated and deleted CYP2D6 genesI Johansson, E Lundqvist, M L Dahl, et al.Pharmacogenetics|October 1, 1996
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean populationH K Roh, M L Dahl, I Johansson, et al.Pharmacogenetics|October 1, 1996
CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomesK Nakamura, T Yokoi, K Inoue, et al.Pharmacogenetics|October 1, 1996
Trimethylamine N-oxidation in Turkish women with bacterial vaginosisS Sardas, D Akyol, R L Green, et al.Pharmacogenetics|December 1, 1996
Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeastJ C Gautier, S Lecoeur, J Cosme, et al.Pharmacogenetics|December 1, 1996
Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancerJ Brockmöller, R Kaiser, R Kerb, et al.Pharmacogenetics|December 1, 1996
CYP2C19 genotype and phenotype determined by omeprazole in a Korean populationH K Roh, M L Dahl, G Tybring, et al.Pharmacogenetics|April 1, 1996
Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles CountyS J London, A K Daly, J Cooper, et al.Pageof 83